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1. Introduction  
Searching for the pharmacophoric profile based on the concepts of chemical and structural 
contribution of the receptor active sites as well as receptor ligand interactions are 
fundamental for the development of new potential drugs for several different diseases and 
body dysfunctions such as degenerative brains disorders, Alzheimer disease, Parkinson's, 
diabetes Mielittus, cancer and many others known sickness conditions. 
Basically, a pharmacophore describes the main molecular features regarding the recognition 
of a ligand by a biological macromolecule. In accord to the IUPAC (International Union of 
Pure and Applied Chemistry) Pharmacophore can be considered as “the largest common 
denominator shared by a set of active molecules to specific biological target”(Wermuth et 
al., 1998).  
A pharmacophore is defined by the pharmacophoric descriptors that are a set of electronic, 
structural, electrostatic and topological properties. Those descriptors can be obtained by 
experimental and theoretical studies. Experimental studies like X-ray crystallography, 
spectroscopic measurements are used to define some atomic properties of a molecule, but 
need a previous job – a synthesis of such molecule. Thus, in this way theoretical studies 
eliminate this previous job the in silico experiments or the theoretical studies are important 
tools to know a molecule before this one gets synthesized.  
In modern computational chemistry, pharmacophores are used to define the essential 
features of one or more molecules with the same biological activity. In the past few years, it 
has been common that the drug discovery has a contribution from pharmacophore 
modeling to identify and develop new potential molecules with desired biological effect 
(Steindl et al., 2006). 
Therefore, in order to enhance the insights to identify potential new medicinal drugs many 
computational strategies are widely used (Steindl et al., 2006; Tasso, 2005). Mathematics and 
chemical molecular modeling applied on bioinformatics are important examples of these 
strategies. Multivariate analysis (principal component analysis - PCA) and quantum 
chemistry calculations (density functional theory - DFT) are some of them, and can led  
to the identification of the main information required to describe the essential 
pharmacophore profile.  
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PCA has been used to find new potential molecules in a series of biological systems (Carotti 
et al., 2003; de Paula et al., 2009; Nascimento, et al., 2011). It is a method abundantly used in 
a lot of multivariate analysis (Jolliffe, 2002). This method has two main aims: to decrease 
variable sets in the problems of multivariate data and to select the best properties (linearly 
independents) that describe the system (principal components). According to Jolliffe (Jollife, 
2002) the central idea of PCA analysis “is to reduce the dimensionality of a data set in which 
there are a large number of interrelated variables, while retaining as much as possible of the 
variation present in the data set. This reduction is achieved by transforming to a new set of 
variables, the principal components, which are uncorrelated, and which are ordered so that 
the first few retain most of the variation present in all of the original variables. Computation 
of the principal components reduces to the solution of an eigenvalue-eigenvector problem 
for a positive-semidefinite symmetric matrix”.  
Although it may seem a simple technique, PCA can be applied in a lot of problems with 
several variables, such as the problems involving the determination of the pharmacophoric 
profile of a particular class of molecules. 
There are different pretreatment methods for the data analysis, e.g., mean-centering and 
autoscaling. This work covers the second method. The autoscaling is very similar to the 
mean-centering with additional paths.  
First, it is calculated the mean of the data matrix X, where the columns correspond to the 
variables and the lines are the samples (or objects). The mean is the jth column vector of a 
data matrix:  
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After mean-centering the standard deviation (Equation 2) for each column is calculated and 
the autoscaling is obtained by the division of standard deviation (Equation 3).  
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Within the autoscaling all variables are adjusted to the same range, such that each variable 
has a zero mean, while the standard deviation is one. Therefore, autoscaling is important for 
data set where the variables have different units. 
DFT is a method to investigate the electronic structure of many-body systems, like atoms and 
molecules (Cramer, 2004). This method can be used to calculate electronic and structural 
properties of molecules with biological activity like new drugs to treat a disease. Applying 
functional that are spatially dependent on the electronic density of multi-electronics systems.  
The application of human and economic resources to improve life quality has promoted 
benefits and has led to the increasing on the number of diseases known as age-dependent. 
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Among these diseases the most frequently are the dementias, diabetes and cardiovascular 
disease. Among the several types of dementia existing and the most common incidents in 
the population over 60 years of age are Alzheimer's disease (AD), vascular dementia and 
Pick's disease. It is estimated that 45 million people worldwide have some kind of dementia, 
among these, 18 million have symptoms characteristic of Alzheimer's disease. AD is a 
disease that has no determined cause, and therefore their treatment is based on drugs that 
only treat the disease in order to remediate the cognitive functions and slow down the 
degenerative advance. (Sugimoto, 2002) 
AD is a kind of dementia that affects neural cognitive function. Thus, one of the most widely 
used strategies for the treatment of this disease consists in blocking off the hydrolysis 
(Figure 1) of the neurotransmitter acetylcholine in cholinergic synapses of neurons, this 
strategy is called cholinergic hypothesis, nowadays a major target in the development of 
drugs that benefits and improves the chemical balance of the concentration of acetylcholine 
in patients with AD (Tezer, 2005; Camps, 2005; Costantino, 2008). 
Some drugs act as inhibitors of AChE, among them, tacrine first drug approved by FDA for 
the treatment of AD (Sugimoto, 2002; Ul-haq, 2010), followed by donepezil (Sippl, 2001), 
rivastigmine (Sugimoto, 2002; Ul-haq, 2010) and galantamine (Sippl, 2001). Other drugs 
have been clinically studied and tested for use in the treatment of AD, such as 
physostigmine (Sippl, 2001; Ul-haq, 2010; Bartolucci, 2006). Some others are being tested and 
are promising candidates for the approval, including, Huperzine A (Patrick, 2005; Barak, 
2005), metrifonate (Sippl, 2001) and phenserine (Sippl, 2001; Ul-haq, 2010). These drugs are 
indicated to treat mild to moderate stages of AD, when the patient still has independent 
cognitive activity.  
 
Fig. 1. Hydrolysis of acetylcholine  
Chemically, the inhibitors mentioned above have in common the inhibitory action of AChE, 
but have different structure and chemical nature. The geometries of some AChEIs are shown 
in Figure 2. Organophosphates, alkaloids and acridines, are some of the classes of drugs that 
inhibit acetylcholinesterase and are used in the treatment of AD. This raises the question: 
what are the electronic, structural, topological and chemical properties that correlate these 
different classes of drugs as inhibitors of the same biological target? 
The brain is the most complex system of the human body and main focus of biochemical 
and neuromolecular studies of the twenty -first century. The research and development of 
drugs that act more effectively in the treatment and the study of brain’s diseases 
mechanisms are subject to various areas of knowledge. 
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PCA have been used to find new potential molecules in a series of biological systems 
(Carotti, 2003, de Paula, 2009; de Paula, 2007; Li, 2009; Nascimento, 2011; Nascimento, 2008; 
Rocha, 2011; Steindl, 2005). A methodology based on PCA for the pharmacophore 
identification of the acetylcholinesterase inhibitors (AChEI) was recently used (de Paula, 
2009; de Paula, 2007; Fang, 2011; Nascimento, 2011; Nascimento, 2008). In this chapter the 
electronic, structural, topological and chemical properties of studied molecules, were taken 
from the theoretical procedures and related to the activity by means of the multivariate 
analysis PCs that provides the pharmacophoric profile of these AChEIs. 
 
 
 
Fig. 2. Structures of some acetylcholinesterase inhibitors. 
2. Mapping the pharmacophoric profile of acetylcholinesterase inhibitors 
2.1 Acetylcholinesterase inhibitors, the AChEIs molecules 
The cholinesterase inhibitors can be used for various purposes, as chemical warfare 
weapons such as sarin gas, in diseases treatment, e.g., the Alzheimer's disease treated with 
rivastigmine. There were used two different concepts to the rational design of inhibitors of 
this enzyme: 
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 drugs that have the molecular recognition in the catalytic site of AChE, doing 
preferably covalent bonds with the hydroxyl of the serine residue 200, this bond may be 
reversible or irreversible; 
 drugs that are recognized by the to active site of the enzyme, which act by blocking the 
entry of the natural substrate, the neurotransmitter acetylcholine at the active site of 
AChE. 
Some drugs that inhibit the function of the enzyme have also neuroprotective function, 
acting more effectively in the AD treatment. These drugs act in a negative way in the 
process of hyperphosphorylation of -amyloid protein, inhibiting the breakdown of this 
protein and consequently the formation of amyloid plaques. 
The inhibitors tacrine (THA), donepezil (E2020), rivastigmine (RIVA), galantamine (GALA), 
metrifonate (METRI), dichlorvos (DDVP), phenserine (PHEN), physostigmine (PHYSO), 
huperzine A (HUPE) and the tacrine dimer (DIMTHA) been studied theoretically by means 
of molecular modeling. From these studies, the mapping of pharmacophoric profile of these 
AChEIs was important to elucidate the correlation of such molecules as drugs to treating 
Alzheimer's disease. 
2.2 Molecular modeling  
Molecular modeling is one of the fields of theoretical chemistry that has been a great 
development in recent decades. The rational drug design is an area of application of 
molecular modeling of high relevance. Predict computationally a molecule with 
pharmacological activity and a drug candidate brings the expectation of reducing the search 
time and the cost in the molecular synthesis process and the clinical tests in vitro and in vivo. 
The molecular modeling is characterized by applications of classical mechanics, quantum 
mechanics and stochastic methods like Monte Carlo in chemical and biochemical systems. 
One possibility is the prediction of spatial behavior and chemical interaction between a 
receptor and its biological substrate (ligand). Another is the calculation of molecular 
properties relevant to determining how this interaction takes place. Modeling the system 
receptor-ligand (RL) is possible to obtain important information about the interactions. 
These RL interactions establish the functionality of a given molecule. However, only the 
studies of interactions do not provide enough parameters to the development of new ligand.  
The properties of a molecule can be obtained by theoretical calculations using classical 
mechanics and quantum mechanics. In the molecular mechanics approach, the classical 
mechanics deals with the problem without taking into account the electrons. Thus, 
electronic properties can only be treated by methods of electronic structure by means of 
quantum mechanical calculations. The main properties that describe a molecule are 
classified according to how it is defined spatially. 
With the development of computational tools (hardware and software) it is possible today 
to treat complex molecular systems using approximate methods of quantum theory. 
Quantum mechanics considers that the energy of a molecule can be described as a sum of 
terms of energy resulting from electrostatic interactions between core and electrons (kinetic 
and potential energy). The fundamental postulate of quantum mechanics describes a wave 
function for each chemical system where a mathematical operator can be applied to this 
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function resulting in observable properties of such system. Equation 4 is the focus of the 
study of quantum methods for the description of chemical systems and is known as the 
Schrödinger equation, independent of time and without relativistic corrections; 
 H = E (4)
where H is a mathematical operator that returns the energy eigenvalue of the system as an 
operator called the Hamiltonian.  is the wave function that describes the system state from 
the coordinates of the positions of nuclei and electrons of the atoms in the molecule. E is the 
eigenvalue, and represents the total energy of the system. 
2.2.1 Computational modeling of AChEIs 
The theoretical studies of AChEIs were performed using the Gaussian03 program package 
(Frisch, 2004) in order to determine the best electronic and geometrical parameters of 
AChEIs molecules. Was have used DFT at the B3LYP hybrid functional level with 6-
31+G(d,p) basis set. The geometries of the target drugs were first optimized using internal 
coordinates in order to minimize all geometric data.  
AChEI structures were taken from Protein Data Bank (PDB). Specifically, the structure of 
AChEI complexed with AChE included the inhibitors tacrine (PDB code 1ACJ), 
galantamine (PDB code 1DX), donepezil (PDB code 1EVE), tacrine dimer (PDB code 
2CKM), huperzine A (PDB code 1VOT) and rivastigmine (PDB code 1GQR). However, the 
three-dimensional structures of physostigmine, phenserine, metrifonate and dichlorvos 
were not found in a complex with AChE, and so the structures were modeled using the 
GaussView 4.1 program.  
In order to analyze the activity of such AChEIs, we have computed the electronic and 
structural properties of those molecules: dipole, frontier molecular orbital energies Highest 
Occupied Molecular Orbital and Lowest Unoccupied Molecular Orbital (HOMO, HOMO-1, 
LUMO and LUMO+1), charge of heteroatoms, charge of most acid hydrogens, volume, 
distance between the most acid hydrogens – H-H, molecule size, LogP (partition 
coefficient/lipophilicity), LogS (solubility), number of H-bond acceptors, number of H-bond 
donors, number of aromatic rings, gap (HOMO-LUMO), and map of electrostatic potential 
(MEP). The charge used was from the ChelpG (i.e., the charge from electrostatic potentials 
using a grid-based method) population analysis.  
2.3 Electronic structure of AChEI molecules 
Table 1 shows the values for some calculated properties for the studied AChEIs. The values 
of the HOMO orbital energies are different when comparing the organophosphate DDVP 
and METRI (higher values) and other AChEIS. Thus, the values of the orbital HOMO-1 
energy for these organophosphates are almost similar while the values of this energy for 
other AChEIS, structurally different, are between -6.04 and -6.75, indicating that this orbital 
may be important in process of interaction of these drugs with acetylcholinesterase.  
Properties such as volume, size of the molecule, logP and dipole have different values for 
each AChEI. Although some of these molecules are of the same class, the calculated values 
for the same property changes sharply, as the volume between DDVP and METRI.  
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 DDVP METRI DIMTHA THA HUPE GALA E2020 PHYSO RIVA PHEN 
Dipole (D) 3.04 2.93 2.09 3.51 6.08 1.67 2.48 1.08 2.53 1.85 
Charge H+ (ua) 0.070 0.438 0.260 0.339 0.365 0.371 0.136 0.333 0.103 0.281 
Charge N (ua) 0 0 -0.320 -0.766 -1.013 -0.632 -0.484 -0.619 -0.378 -0.753 
Charge O( ua) -0.638 -0.639 0 0 -0.670 -0.685 -0.554 -0.659 -0.594 -0.505 
HOMO (eV) -6.86 -8.11 -5.90 -5.76 -5.90 -5.53 -5.95 -5.46 -5.79 -5.23 
HOMO-1 eV) -8.57 -8.30 -6.71 -6.56 -6.75 -6.04 -6.05 -6.08 -6.53 -6.43 
LUMO (eV) -0.54 -1.59 -1.47 -1.28 -1.30 -0.48 -1.53 -0.33 -0.43 0.52 
LUMO+1(eV) 0.42 0.70 -0.58 -0.46 0.36 -0.14 -0.48 -0.07 0.21 0.51 
GAP (eV) 6.32 6.52 4.47 4.49 4.60 5.53 4.41 5.12 5.36 5.75 
H-H (Å) 1.796 2.307 1.998 1.683 1.625 2.373 2.342 2.324 2.460 2.250 
Volume (Å3) 185 207 606 236 286 329 454 321 312 332 
Size (Å) 7.849 7.068 19.386 9.516 9.051 10.290 12.281 12.927 11.242 14.808 
logP 1.66 0.80 3.88 3.13 2.60 1.39 4.14 1.94 2.86 2.99 
logS -1.44 -1.77 -4.98 -3.16 -2.47 -2.23 -4.93 -2.44 -1.89 -4.2 
PSA(Å2) 44.8 55.8 58.5 38.9 58.9 41.9 38.8 44.8 32.8 44.9 
H-donnor 0 1 4 2 2 1 0 1 0 1 
H-acceptor 4 4 4 2 4 4 4 5 4 5 
Aromatic ring 4 0 4 2 1 2 2 2 1 1 
H+: most acid hydrogen of the molecule. H-H: distance between the most acid hydrogens. 
Table 1. Electronic and structural data of AChEIs from B3LYP/6-31+G(d,p) level of 
calculation.  
The distribution of frontier orbitals in the molecule is important to determine which atoms 
are most relevant for the interaction between the ligand and the receptor, during the activity 
of such drug with the biological target. Figure 3  shows the regions of the frontier orbitals of 
RIVA. The LUMO of RIVA is located in an unusual region for orbitals poor in electrons, 
since the benzyl ring is by definition the region of high electronic density. RIVA have the 
HOMO and LUMO in the opposite region of carbamate moiety.  
 
Fig. 3. HOMO and LUMO of RIVA calculated at B3LYP/6-31+G (d,p) level. 
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Figure 4 shows the MEP for all drugs studied. The maps indicate that all AChE have well-
defined regions of high electron density (red) and low density (dark blue). These regions are 
likely points of interaction with AChE through electrostatic interactions like hydrogen 
bonding. Other electron density regions of AChE present mostly negative, indicating that 
these regions may have electrostatic interactions such as charge transfer, interactions with 
 systems of aromatic residues in the active site of AChE. According to the literature 
(2003; de Paula et al., 2009; Nascimento, et al., 2011) RIVA interacts with the Ser200 residue 
of the catalytic triad through the carbamoyl moiety.  
The regions of highest electronic density are located under the oxygen atoms in DDVP, 
METRI, HUPE, GALA, E2020, PHYSO, RIVA suggesting that these oxygens are receptors  of 
hydrogens that can share in interactions, such as hydrogen bonding with the residues of the 
AChE catalytic triad or promoting covalent bonds, with the hydroxyl group of Ser200 
(Camps, 2002). The rivastigmine (Figure 4h) and donepezil (Figure 4f) have more regions 
with low electronic density than other drugs, which is important for the interaction with the 
receptor site. The molecular volume is an important descriptor for drug design, and it is 
shown that some inhibitors are more linear which should improve the binding to two or 
more parts of the enzyme.   
2.4 Mapping of the pharmacophoric profile of AChEIs via PCA 
The mapping of pharmacophoric profile of AChEIs was conducted by means of PCA 
analysis, using of the data set obtained from calculations of the properties obtained for each 
molecule. For the analysis of principal components the geometry optimizations were 
performed at the level B3LYP/6-31 + G (d, p). The properties amount is shown in Table 1. 
PCA was used to correlate 18 properties of 10 AChEI molecules to reduce the initial 
parameter set and determine the most relevant data for the acetylcholinesterase inhibition. 
PCA was conducted using the autoscaling method because the structural and electronic 
properties have different dimensions. 
Since the structural and electronic properties have very different dimensions, autoscaling 
method is required. This normalization method consists in moving and stretching axes, 
centering the data on average and divides them by their standard deviation. Thus, each 
variable present zero mean and variance equal 1, giving the same significance for all 
variables (Jolliffe, 2002). 
The first PCA showed that 83.3% on average of the information set formed by 10 AChEIs 
and 18 properties, obtained through the calculation performed in this work can be 
represented by four principals components (38.3% variance to PC1; 59.2% cumulative 
variance to PC2, 73.2% cumulative variance to PC3, 83.3% cumulative variance to PC4). 
In studies of systems of many variables with PCA, it is desirable the lowest possible number 
of principal components that properly represent over 90% of cumulative variance. Thus, to 
increase the accuracy and determine the principal components we have used all 
combinations of 18 properties for the 10 AChEIs studied. Then the PCA was taken from the 
most relevant properties in relation to the total variance with the lower number of  
principal components.  
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Fig. 4. Map of electrostatic potential of AChEIs calculated at B3LYP/6-31+G(d,p) level. (a) 
tacrine, (b) tacrine dimer, (c) huperzine A, (d) phenserine, (e) galantamine, (f) donepezil, (g) 
metrifonate, (h) rivastigmine, (i) dichlorvos. 
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In a second part, only 6 variables were used (shown below) with the 10 objects (AChEIs), 
these results in a 92% of total variance with information that characterizes these drugs in 
three principal components. Therefore, PCA (Figure 5) suggests that following properties 
are responsible for 92% of variance (63.5% for PC1 and 19.1% for PC2): volume, size of the 
molecule, distance between the two most acid hydrogens, energy of HOMO-1 frontier 
orbital, logP partition coefficient, and the number of aromatic rings (Table 2). In other 
words, these properties describes well the whole set of molecules data.  
 
 PC1 PC2 PC3 
B3LYP/6-31+G(d,p) 63.5 % 82.6% 91.7% 
Table 2. Total cumulative variance (%) using 10 AChEIs and 6 properties 
Equations 5, 6 and 7 show the scores of the PC1, PC2 and PC3. The PC1 is essentially the 
volume, size, partition coefficient- log P and number of aromatic rings of the drug 
(structural and electronic parameters), the PC2 represents the distance H-H (structural 
parameter) while the PC3 mainly represents the energy of the HOMO-1 orbital (electronic 
parameter). 
 PC1= 0.48volume + 0.46Size + 0.13H-H + 0.37HOMO-1 + 0.42logP + 0.44Arom.  (5) 
 PC2=-0.01volume + 0.02Size + 0.88H-H + 0.28HOMO-1 – 0.33logP – 0.19Arom.  (6) 
 PC3=-0.38volume – 0.40Size – 0.16H-H + 0.79HOMO-1 + 0.18logP + 0.04Arom. (7) 
Figure 5 shows that the molecules are grouped into some main groups in regard to PC1, one 
of these are the GALA, RIVA, PHEN and PHYSO which forms a cluster and these are the 
FDA approved drugs. HUPE, THA form other group with two potent inhibitors 
acetylcholinesterase. Therefore, volume,  systems and drug size are important 
parameters that correlate the AChEIs. 
On other hand PC2 is dominated by the HH distance (score: +0.88), which separates 
compounds according to the distance between the two hydrogens more acidic in two 
groups: one that found them have H-H values smaller than 2.0 Å, and other group of objects 
that have values greater than those cited. 
Figure 6 depicts the scores of PC1 versus PC3. In this case there are two standards in PC3 
DDVP / METRO and GALA / PHYSO / RIVA / PHEN, this is reasonable, since PC3 
represent the orbital energy of HOMO-1 (+0.79) (Equation 7), these AChEIs have values close 
to the HOMO-1 and the volume, as shown in Table 1. Figures 5 and 6, Equations (5, 6 and 7) 
generated in the PC indicates that the electronic parameters - orbital energy of HOMO-1 , log P 
and number of aromatic systems - and the structural parameters - volume, size of the drug and 
H-H- are the most significant properties of AChE in this multivariate analysis. 
3. Applications of PCA from pharmacophoric profile of the AChEIs 
From the pharmacophore profile determined by means of PCA and electronic structure 
calculations, other classes of molecules can be considered to be classified as AChEI. 
Therefore, it is important to note that, when added other objects, the new plotted PCs 
should have accumulative variance equal or larger than the original PCA (Table 3). That is, 
the original data set is the reference.  
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Fig. 5. PC1 versus PC2 scores from B3LYP/6-31+G(d,p) data.  
 
 PC1 PC2 PC3 
B3LYP/6-31+G(d,p) 71 % 86% 94% 
Table 3. Total cumulative variance (%) using 10 AChEIs, 2 new molecules, 1 substrate and 6 
properties. 
 
Fig. 6. PC1 versus PC3 scores from B3LYP/6-31+G(d,p) data.  
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The following are some applications explored. One possible application is the identification 
of dual biological activity of molecules. Another is the identification of activity against the 
function of acetylcholinesterase inhibitor, i.e., how behaves the natural substrate of  
the enzyme. 
MOL1 and MOL2 with different biological activity from AChEIs were studied. We have also 
added another compound on the data set, acetylcholine (acetylcholinesterase substrate). 
Within these data from the properties obtained through electronic structure calculations, the 
new PCA was generated. These three objects were added to the 10 other objects of the first 
PCA which determined the pharmacophoric profile of AChEIs. 
As shown in Figure 7, the natural substrate reorients the axis of the PCs and is completely 
opposed to the other (active) drugs. The acetylcholine is close to some of AChEIS by PC1, 
which have the properties of volume, size and number of aromatic rings with more high 
scores. Although acetylcholine is not an inhibitor it must have some properties correlated 
with the AChEIs. All molecules that are recognized by a protein have a certain set of 
properties that allows this recognition. 
 
Fig. 7. PC1 versus PC2 scores from 10 AChEIs, 2 new molecules and ACh at B3LYP/6-
31+G(d,p) level.  
According to the PCA the two new drugs can be classified as AChEIs, although it is not 
possible to determine whether they have efficacy in the treatment of Alzheimer's disease. It 
is important to note that the effectiveness of a drug depends also on other factors that are 
difficult or much complex for modeling. 
As shown in Figure 7, the natural substrate reorients the axis of the PCs and is completely 
opposed to the other (active) drugs. The acetylcholine is close to some of AChEIs by PC1, 
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which have the properties of volume, size and number of aromatic rings with large scores. 
Although acetylcholine is not an inhibitor it must have some properties correlated with  
the AChEIs.  
All molecules that are recognized by a protein have a certain set of properties that allows 
this recognition. As shown in Figure 8, in the case of acetylcholinesterase specifically, 
molecular modeling studies showed that during the molecular recognition of acetylcholine, 
the quaternary nitrogen of the substrate has a strong ionic interaction with the carboxyl 
group of the residue Asp72. In addition, there is formation of hydrogen bonds between the 
amine and ester group of the residue Asn65 and Tyr130 (Patrick, 2005). 
 
Fig. 8. PC1 Optimized structure of acetylcholine and main points of molecular recognition in 
acetylcholinesterase at B3LYP/6-31+G(d,p) level.  
4. Conclusion 
All studied AChE inhibitors are recognized as drugs that act effectively in the treatment of 
AD, even if some are not recommended due to unwanted side effects. From the computer 
modeling, applied by electronic structure calculations and PCA of known AChEIs with 
potential for the treatment of AD, it is possible to conclude that the properties relevant to the 
inhibitory activity are: 
1. The HOMO-1 orbital is the most important property, characteristic of all drugs. 
2. The study of the electrostatic potential map indicates that all AChEIs have well-defined 
regions of high and low electronic density, and these regions are the likely points of 
interaction with acetylcholinesterase, through electrostatic interactions such as 
hydrogen bonding. In some cases, such as dichlorvos, rivastigmine and physostigmine, 
it is possible to predict a bond with covalent character to the catalytic triad of the 
enzyme. 
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3. The H-H distance between 1.625-2.460Å, volume, and logP are also relevant for the 
pharmacophoric profile. 
4. The electronic properties - orbital energy of the HOMO-1, log P and number of aromatic 
systems - and the structural parameters volume, size of the drug and H-H distance are 
the most significant properties in this study, the main components of the 
pharmacophore profile of AChEIs. 
5. From the pharmacophore profile determined using PCA and electronic structure 
calculations, other classes of molecules can be considered to be classified as AChEI. 
In addition to the structural and electronic properties mentioned above, an efficient inhibitor 
should have good bioavailability, cross the blood brain barrier with relative ease, to have 
high selectivity for acetylcholinesterase compared to butilcholinesterase; be able to form a 
complex reversible or pseudo-reversibly with AChE, be non-competitive compared to 
natural substrate. All these properties are jointly sharing in the profile of AChE 
pharmacophore studied in this work. 
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